ES2070238T3 - Emulsion de lipidos que contiene un analogo de prostaglandina. - Google Patents

Emulsion de lipidos que contiene un analogo de prostaglandina.

Info

Publication number
ES2070238T3
ES2070238T3 ES90119772T ES90119772T ES2070238T3 ES 2070238 T3 ES2070238 T3 ES 2070238T3 ES 90119772 T ES90119772 T ES 90119772T ES 90119772 T ES90119772 T ES 90119772T ES 2070238 T3 ES2070238 T3 ES 2070238T3
Authority
ES
Spain
Prior art keywords
prostaglandin
analog
emulsion containing
lipid emulsion
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90119772T
Other languages
English (en)
Inventor
Yutaka Mizushima
Toshihide Seikagaku Ko Inomata
Arata Yasuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seikagaku Corp
AGC Inc
Original Assignee
Asahi Glass Co Ltd
Seikagaku Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Glass Co Ltd, Seikagaku Corp filed Critical Asahi Glass Co Ltd
Application granted granted Critical
Publication of ES2070238T3 publication Critical patent/ES2070238T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)

Abstract

UNA EMULSION DE LIPIDO QUE CONTIENE UN ANALOGO DE PROSTAGLANDINA DE LA FORMULA (1): EN DONDE R1 ES UN GRUPO ALCANOILO, R2 ES UN ATOMO DE HIDROGENO O UN GRUPO ALQUILO, CADA UNO DE R3 Y R4 ES UN ATOMO DE HIDROGENO O UN GRUPO PROTECTOR PARA UN ALCOHOL, R5 ES UN GRUPO ALQUILO, EL CUAL PUEDE TENER UN SUSTITUYENTE, Y ES UN SIMPLE ENLACE O UN DOBLE ENLACE.
ES90119772T 1989-10-16 1990-10-15 Emulsion de lipidos que contiene un analogo de prostaglandina. Expired - Lifetime ES2070238T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1266230A JP2602964B2 (ja) 1989-10-16 1989-10-16 プロスタグランジン類縁体およびその脂肪乳剤

Publications (1)

Publication Number Publication Date
ES2070238T3 true ES2070238T3 (es) 1995-06-01

Family

ID=17428079

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94111337T Expired - Lifetime ES2132279T3 (es) 1989-10-16 1990-10-15 Analogo de prostaglandina.
ES90119772T Expired - Lifetime ES2070238T3 (es) 1989-10-16 1990-10-15 Emulsion de lipidos que contiene un analogo de prostaglandina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES94111337T Expired - Lifetime ES2132279T3 (es) 1989-10-16 1990-10-15 Analogo de prostaglandina.

Country Status (10)

Country Link
US (1) US5120870A (es)
EP (2) EP0423697B1 (es)
JP (1) JP2602964B2 (es)
AT (2) ATE179169T1 (es)
AU (1) AU641436B2 (es)
CA (1) CA2027351C (es)
DE (2) DE69016567T2 (es)
DK (2) DK0423697T3 (es)
ES (2) ES2132279T3 (es)
GR (2) GR3015963T3 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU684133B2 (en) * 1994-01-18 1997-12-04 Teijin Limited 7-thiaprostaglandins and process for producing the same
CA2302023A1 (en) * 1997-08-27 1999-03-04 Yoshitomi Pharmaceutical Industries Ltd. Angiogenesis promoter
JP4386581B2 (ja) * 1998-06-04 2009-12-16 旭硝子株式会社 精製されたプロスタグランジン誘導体の製造方法
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
EP1429749A2 (en) 2001-09-26 2004-06-23 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
JP2003342196A (ja) * 2002-05-31 2003-12-03 Mukku:Kk 静脈注射用組成物、その製造法およびその製剤
WO2005077337A2 (en) * 2004-02-05 2005-08-25 Baxter International Inc. Dispersions prepared by use of self-stabilizing agents
ES2314354T3 (es) 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
AU2005304034B2 (en) * 2004-11-09 2012-02-16 Santen Sas Ophthalmic emulsions containing an immunosuppressive agent
EP1937212B1 (en) * 2005-10-10 2010-09-01 Novagali Pharma S.A. Ophthalmic emulsions containing prostaglandins
RU2470644C2 (ru) 2006-09-05 2012-12-27 Кью.Пи. КОПЭРЕЙШН Стабильная жировая эмульсия (варианты), способ ее получения, эмульгирующий агент и способы стабилизации простагландина и капель жира
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4363817A (en) * 1981-08-27 1982-12-14 Miles Laboratories, Inc. Enol acylate analogs of E1 and E2 prostaglandins
JPS58222014A (ja) * 1982-06-18 1983-12-23 Taisho Pharmaceut Co Ltd プロスタグランジンｅ↓１脂肪乳剤
JPS59216820A (ja) * 1983-05-20 1984-12-06 Taisho Pharmaceut Co Ltd プロスタグランジン脂肪乳剤
JPH0818989B2 (ja) * 1984-01-12 1996-02-28 株式会社ミドリ十字 脂肪乳剤中のプロスタグランジンの安定化方法
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
JPS61151126A (ja) * 1984-12-25 1986-07-09 Teijin Ltd △７―プロスタグランジンａ１類を有効成分として含有する注射用の脂肪乳剤

Also Published As

Publication number Publication date
EP0624574A3 (en) 1995-01-18
DE69016567T2 (de) 1995-09-21
DE69033069T2 (de) 1999-08-19
EP0423697A2 (en) 1991-04-24
EP0624574A2 (en) 1994-11-17
DK0624574T3 (da) 1999-10-25
DE69016567D1 (de) 1995-03-16
EP0423697B1 (en) 1995-02-01
ES2132279T3 (es) 1999-08-16
AU6452690A (en) 1991-04-18
DK0423697T3 (da) 1995-05-29
GR3030718T3 (en) 1999-11-30
AU641436B2 (en) 1993-09-23
EP0624574B1 (en) 1999-04-21
CA2027351C (en) 2001-06-19
US5120870A (en) 1992-06-09
ATE117989T1 (de) 1995-02-15
EP0423697A3 (en) 1992-08-05
GR3015963T3 (en) 1995-07-31
DE69033069D1 (de) 1999-05-27
ATE179169T1 (de) 1999-05-15
JPH03204853A (ja) 1991-09-06
CA2027351A1 (en) 1991-04-17
JP2602964B2 (ja) 1997-04-23

Similar Documents

Publication Publication Date Title
ES2070238T3 (es) Emulsion de lipidos que contiene un analogo de prostaglandina.
DK0521550T3 (da) Vitamin D forbindelse, fremgangsmåde til fremstilling af denne forbindelse og mellemprodukt derfor
FI92695B (fi) Uusi menetelmä heksa-, okta- tai dekahydronaftyylietyylisubstituoitujen 4-hydroksitetrahydropyran-2-onijohdannaisten valmistamiseksi
ES2140456T3 (es) Derivado de diester fosfonico.
MX9204661A (es) Compuestos intermedios derivados de eter y procedimiento para su preparacion.
ES2054732T3 (es) Un procedimiento para preparar un derivado peptidico.
ES2058176T3 (es) Un procedimiento para preparar un derivado peptidico.
FI901277A0 (fi) 2,5,6,7-tetranor-4,8-inter-m-fenylen pg1z-derivativ.
ES537558A0 (es) Un procedimiento para la preparacion del isomero r (dextrogiro)
DE3677465D1 (de) N-glykolylneuraminsaeurederivat.
ATE29487T1 (de) Fluorierte diaminohepten- und -heptin-derivate.
DK36689D0 (da) Fremgangsmaade til fremstilling af et 16-methoxy-16-methyl-prostaglandin e1-derivat, samt ved fremgangsmaaden anvendelige mellemprodukter
GR910100519A (el) Μεθοδος για την παρασκευη ναπροξενιουχου κητιλτριμεθυλαμμωνιου.
ES2083961T3 (es) Acidos 3-anilino-2-hidroxicarbonil-4-tiofenoaceticos.
DE58909745D1 (de) Tetrahydro-4-phenylimino-3-thiophenessigsäuren

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 423697

Country of ref document: ES